Royal Bank of Canada (RBC) has filed a pricing supplement to offer Digital Notes linked to the performance of NVIDIA Corporation's common stock. The offering, totaling $696,000, is a strategic move by RBC to expand its financial product offerings in the commercial banking sector.
The Digital Notes, due November 9, 2029, will provide investors with a contingent fixed return of 31.90% if the stock performs well. However, if the stock value declines, investors will only receive their principal back. This structure highlights the risks associated with such investments, as noted in the filing.
Background
Royal Bank of Canada, identified by the Central Index Key (CIK) 0001000275, operates primarily in the commercial banking sector (SIC 6029). The bank is listed on the New York Stock Exchange under the ticker symbol RY and also trades on the OTC market under RYLBF. Recent filings include multiple pricing supplements and a Schedule 13G/A.
What the Filing Says
The recent filing dated November 10, 2026, outlines the terms of the Digital Notes, stating: "Royal Bank of Canada is offering Digital Notes linked to the performance of the common stock of NVIDIA Corporation." The total amount offered is $696,000, with no underwriting commissions involved.
Impact
This offering may impact various stakeholders, including investors looking for alternative investment options and competitors in the commercial banking sector. The unique structure of the Digital Notes may attract investors interested in high-risk, high-reward scenarios.
What's Next
The filing does not specify what happens next regarding the offering, but interested investors may need to review additional documents provided in the prospectus and related supplements.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










